Breaking News Instant updates and real-time market news.

MLHR

Herman Miller

$37.30

0.2 (0.54%)

, LCI

Lannett

$4.85

0.15 (3.19%)

18:56
09/19/18
09/19
18:56
09/19/18
18:56

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Herman Miller (MLHR) up 10.7%. ALSO HIGHER: Lannett (LCI) up 4.1% after MintBroker disclosed passive stake... Avon Products (AVP) up 2.2% after cutting 100 staff positions... New Gold (NGD) up 1.8% after selling Mesquite Mine... AMD (AMD) up 0.5% after raised price target at Stifel. DOWN AFTER EARNINGS: Red Hat (RHT) down 4.0%. ALSO LOWER: Molecular Templates (MTEM) down 14.4% after equity offering... CRISPR Therapeutics (CRSP) down 4.4% after equity offering... Kosmos Energy (KOS) down 3.9% after mixed shelf offering... Viking Therapeutics (VKTX) down 1.3% equity offering.

MLHR

Herman Miller

$37.30

0.2 (0.54%)

LCI

Lannett

$4.85

0.15 (3.19%)

AVP

Avon Products

$2.32

0.03 (1.31%)

NGD

New Gold

$1.10

0.03 (2.80%)

AMD

AMD

$31.20

-0.73 (-2.29%)

RHT

Red Hat

$143.38

0.59 (0.41%)

MTEM

Molecular Templates

$6.25

2.15 (52.44%)

CRSP

Crispr Therapeutics

$51.90

-1.27 (-2.39%)

KOS

Kosmos

$9.35

0.04 (0.43%)

VKTX

Viking Therapeutics

$19.64

0.17 (0.87%)

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 23

    Sep

  • 27

    Sep

  • 01

    Oct

  • 20

    Sep

  • 21

    Sep

  • 21

    Sep

  • 21

    Sep

MLHR Herman Miller
$37.30

0.2 (0.54%)

12/26/17
RAJA
12/26/17
UPGRADE
Target $43
RAJA
Outperform
Herman Miller upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Budd Bugatch upgraded Herman Miller to Outperform and established a $43 price target following newly passed tax reform. The analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases given immediate expensing of short-term capital assets.
12/26/17
12/26/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LCI Lannett
$4.85

0.15 (3.19%)

08/20/18
08/20/18
DOWNGRADE

Market Perform
Lannett downgraded to Market Perform as JSP walks away from renewal at Raymond James
As previously reported, Raymond James analyst Elliot Wilbur downgraded Lannett to Market Perform from Outperform after Jerome Stevens terminated its strategic distribution agreement with the company, a deal that provided Lannett with several key products but mainly levothyroxine, which is expected to account for 35% of FY18 sales and 44% of gross profit. From a monetary perspective, the analyst believes it makes "zero sense" why JSP would walk away from the deal, inflicting significant damage on its own holdings of Lannett shares. This suggests either JSP has no confidence in the recovery value of its holdings from current levels or has sold down or hedged a substantial portion of its holdings despite prior representations from Lannett management to the contrary, Wilbur contends.
08/20/18
BMOC
08/20/18
NO CHANGE
BMOC
Market Perform
Lannett price target lowered to $8 from $19 at BMO Capital
BMO Capital analyst Gary Nachman said JSP's decision to not renew its agreement with Lannett (LCI) and go with Amneal Pharmaceuticals (AMRX) is an "unfortunate development" that impacts three products, including Levothyroxine, which accounts for about 35-40% of Lannett revenue and is "very profitable." He lowered his estimates "significantly" due to this "major setback" and cut his price target on Lannett shares to $8 from $19 while maintaining a Market Perform rating on the shares.
08/20/18
RAJA
08/20/18
DOWNGRADE
RAJA
Market Perform
Lannett downgraded to Market Perform from Outperform at Raymond James
08/20/18
08/20/18
DOWNGRADE
Target $7

Hold
Lannett downgraded to Hold on end of JSP relationship at Craig-Hallum
As previously reported, Craig-Hallum analyst Matt Hewitt downgraded Lannett to Hold from Buy, stating that the ending of the company's "fruitful long-time partnership" with Jerome Stephens Pharmaceuticals is a "significant disappointment" that creates a noticeable cash flow void and creates a risk that the company's debt gets refinanced at higher interest rates. Separate from the JSP announcement, Lannett also preannounced Q4 results that were below consensus, noted Hewitt, who lowered his price target on the stock to $7 from $32. Lannett shares, which were also downgraded earlier to Neutral from Buy at Roth Capital, are down $7.92, or 59%, to $5.58 in afternoon trading.
AVP Avon Products
$2.32

0.03 (1.31%)

01/04/18
BOFA
01/04/18
DOWNGRADE
Target $2.5
BOFA
Underperform
Avon Products downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Avon Products to Underperform from Neutral and lowered its price target to $2.50 from $3.50. Analyst Olivia Tong does not expect a quick rebound for Avon in 2018 following underwhelming 2017 results and sees continued risk to sales, margins, and cash flow.
09/18/18
DADA
09/18/18
NO CHANGE
DADA
Neutral
Avon CEO likely to get time before board considers sale, says DA Davidson
DA Davidson analyst Linda Bolton Weiser thinks the board of Avon Products (AVP) will give new CEO Jan Zijderveld a period of time to improve financial performance before seriously considering a sale of the company. With Zijderveld set to unveil his turnaround strategy on September 21, the Wall Street Journal reported last night that Brazilian beauty direct seller Natura recently approached Avon about a takeover, Bolton Weiser tells investors in a research note titled "What Will Become of Avon?" Natura said in a statement, however, that there are no negotiations in progress concerning a possible acquisition of Avon, the analyst points out. She doubts that the board and Cerberus would find it prudent to sell the company when the share price is around $2. With that said, Bolton Weiser notes that Avon's takeout valuation is $7.75 per share based on Coty's (COTY) 2012 offer. In April 2012, Coty offered $23.25 per share for Avon, a 27% premium, and later raised it to $24.75 per share, or $10.7B, the analyst recalls. She notes the offer was withdrawn in May 2012. Bolton Weiser has a Neutral rating on Avon Products with a $1.75 price target. The stock in late morning trading is up 8%, or 16c, to $2.24.
07/18/18
JEFF
07/18/18
UPGRADE
Target $1.5
JEFF
Hold
Avon Products upgraded to Hold from Underperform at Jefferies
Jefferies analyst Stephanie Wissink upgraded Avon Products to Hold while lowering her price target for the shares to $1.50 from $2. The analyst, who admits she has "limited confidence" in company's fundamentals and sees ongoing risk to sales drivers, believes shares of Avon are close to fair value. Wissink believes new management at Avon are exhibiting a "refreshing sense of urgency."
07/18/18
07/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comerica (CMA) upgraded to Outperform from In Line at Evercore ISI with analyst John Pancari saying he expects earnings growth to outpace peers while returns continue to strengthen, supported by a favorable positioning for higher short-term rates, ongoing efficiency improvement, and intact credit. 2. BorgWarner (BWA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Richard Kwas saying he sees limited share price downside risk and disproportionate upside potential from the current share price. 3. Avon Products (AVP) upgraded to Hold from Underperform at Jefferies with analyst Stephanie Wissink saying she believes shares of Avon are close to fair value. 4. Sunoco (SUN) upgraded to Hold from Underperform at Jefferies with analyst Christopher Sighinolfi saying while he still expects a 30% distribution cut and "equity needs" resulting from elevated leverage, he no longer sees "sufficient downside" with the shares down 10% since early April. 5. CSX (CSX) upgraded to Buy from Hold at Loop Capital with analyst Rick Paterson saying CSX is making "continued progress on the adoption of its scheduled operating model," delivering an operating ratio of 59.8% in Q2 vs. 64.7% last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
NGD New Gold
$1.10

0.03 (2.80%)

08/20/18
ADAM
08/20/18
UPGRADE
ADAM
Hold
New Gold upgraded to Hold from Sell at Canaccord
08/20/18
ADAM
08/20/18
UPGRADE
ADAM
Hold
New Gold upgraded to Hold at Canaccord
As reported previously, Canaccord analyst Rahul Paul upgraded New Gold to Hold from Sell. The analyst believes the recent share price decline of 45% now provides a more balanced risk/reward trade-off, particularly for long-term investors with a bullish outlook for gold. Paul has a C$1.50 price target on New Gold shares.
08/15/18
RBCM
08/15/18
DOWNGRADE
Target $1.4
RBCM
Underperform
New Gold downgraded to Underperform at RBC Capital on eroding cash flow
As reported earlier, RBC Capital analyst Dan Rollins downgraded New Gold to Underperform from Sector Perform and lowered his price target to $1.40 from $3.50. The analyst cites elevated financial leverage and "material" reduction in free cash flow, along with continued risk related to Rainy River mine ramp. Rollins believes that although New Gold has underperformed the broader gold mining ETF GDX by 30%, it will continue to underperform until its risks diminish.
08/15/18
RBCM
08/15/18
DOWNGRADE
RBCM
Underperform
New Gold downgraded to Underperform from Sector Perform at RBC Capital
AMD AMD
$31.20

-0.73 (-2.29%)

09/18/18
MZHO
09/18/18
NO CHANGE
Target $36
MZHO
Buy
AMD price target raised to $36 from $20 at Mizuho
Mizuho analyst Vijay Rakesh raised his price target for AMD (AMD) to $36 from $20 after meeting PC supply chain companies in Asia. The chipmaker closed yesterday down 29c to $32.43. AMD's expected server EPYC shipment spike in Q4 will be key, as Intel (INTC) continues to lack a CEO and a competitive technology response to AMD's 12nm Ryzen and 7nm Vega launch, Rakesh tells investors in a research note. The analyst, who admits there could be "near-term bumps," keeps a Buy rating on shares of AMD after raising his server estimates.
09/19/18
MSCO
09/19/18
NO CHANGE
Target $28
MSCO
Underweight
Morgan Stanley raises AMD price target to $28 from $11, stays Underweight
Morgan Stanley analyst Joseph Moore said each of Intel's (INTC) serial delays in 10 nm output have caused disruptions to the existing roadmaps and now fairly severe shortages. The disruption in Intel's planning cycle has opened the door for AMD (AMD) in multiple ways, said Moore, who admits that the near-term CPU opportunity is larger than he had thought, mostly because of client shortages on Intel's side. AMD's processor opportunity in 2019 seems in-line with his prior view, but probably with less risk than he previously assumed, Moore added. He raised his AMD estimates for desktop and notebook penetration in the second half of 2018 and first half of 2019, mostly due to Intel shortages, and increased his price target on AMD shares to $28 from $11. However, he keeps an Underweight rating on AMD shares, as he lowered his estimates for graphics, which "remains substantially larger than processors." Moore cut his price target on Intel to $50 from $56 and keeps an Equal Weight rating on its shares, stating that its new CEO is going to "have to confront some harsh realities," but will also have the opportunity to take out costs.
09/18/18
09/18/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN CUTS ESTIMATES, PRICE TARGET ON FACEBOOK: JPMorgan analyst Doug Anmuth lowered his 2019 and 2020 earnings estimates for Facebook (FB) by 5%-6% on the company's bigger investment increases over the next couple years, which he does not believe are fully captured in consensus estimates. Even with Facebook suggesting it could reach mid-30% operating margins in a few or several years, investments in 2019 could be larger than anticipated in consensus estimates, Anmuth said. The analyst also cut his price target for the shares to $195 from $205. However, he kept an Overweight rating on Facebook. PIVOTAL CUTS DISCOVERY TO SELL: Pivotal Research analyst Brian Wieser downgraded Discovery (DISCA) to Sell with an unchanged price target of $26. Despite "tepid" earnings and "underwhelming" longer-term trends, the stock is up 20% over the past month, Wieser noted. While Discovery's agreements with Hulu and Sling are positive, they do not meaningfully alter the company's fundamentals, the analyst added. His price target implies 19% downside from current share levels. MIZUHO BOOSTS AMD PRICE TARGET: Mizuho analyst Vijay Rakesh raised his price target for AMD (AMD) to $36 from $20 after meeting PC supply chain companies in Asia. AMD's expected server EPYC shipment spike in Q4 will be key, as Intel (INTC) continues to lack a CEO and a competitive technology response to AMD's 12nm Ryzen and 7nm Vega launch, Rakesh said. The analyst, who admits there could be "near-term bumps," kept a Buy rating on shares of AMD. CANACCORD SAYS KAPERNICK AD HAS 'OVERWHELMING' SUPPORT: Canaccord analyst Camilo Lyon conducted a proprietary survey to assess the impact of Nike's (NKE) "Just Do It" ad featuring former NFL quarterback Colin Kapernick. The findings suggest the impact was overall positive and he expects the company to confirm that when it reports Q1 results next week. He believes the ad has had the intended effect of positively skewing the company's brand perception and likely provided a bump in sales. Lyon reiterated his Buy rating and $95 price target on Nike shares. PIPER, WILLIAM BLAIR DEFEND NUTANIX: Nutanix (NTNX) shares dropped 11.5% Monday due to an article from The Information citing a potential competitive hyperconverged infrastructure offering from Google (GOOG, GOOGL), but Piper Jaffray analyst Andrew Nowinski views the selling pressure as "excessive" and reiterates an Overweight rating on Nutanix with a $66 price target. William Blair analyst Jason Ader called the fear of competition from Google "overblown" and reiterated an Outperform rating on Nutanix.
09/19/18
STFL
09/19/18
NO CHANGE
Target $38
STFL
Buy
AMD price target raised to $38 from $21 at Stifel
Stifel analyst Kevin Cassidy raised his price target on AMD (AMD) to $38 and kept his Buy rating, saying the management has continued its "stellar performance" in executing its plan. The analyst notes that with the 7nm EPYC server CPU sampled by customers, he expects revenue generation to start in the second half of FY19. Cassidy adds that AMD's main competitor Intel (INTC) is struggling to come up with a "competitive response" and also in meeting its current demand, opening the door for AMD to gain market share.
RHT Red Hat
$143.38

0.59 (0.41%)

09/13/18
OTRG
09/13/18
DOWNGRADE
OTRG
Mixed
Red Hat downgraded to Mixed from Positive at OTR Global
09/17/18
RBCM
09/17/18
NO CHANGE
Target $169
RBCM
Outperform
Red Hat price target lowered to $169 from $177 at RBC Capital
RBC Capital analyst Matthew Hedberg lowered his price target on Red Hat to $169 ahead of its earnings this week, saying Q2 is unlikely to be an "inflection-type quarter" and does not expect "improvement in middleware billings quite yet". The analyst notes that based on his checks, he stands behind his Q2 billings forecast of $767M vs. $782.5M consensus. He also believes however that Q3 and Q4 will be better from U.S. federal spending demand and "December budget flush" factors respectively. Hedberg keeps his Red Hat rating at Outperform over the long term and remains positive on the company's "position as an enabler of hybrid-cloud workload".
09/18/18
JPMS
09/18/18
DOWNGRADE
Target $150
JPMS
Neutral
Red Hat downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Mark Murphy downgraded Red Hat to Neutral and lowered his price target for the shares to $150 from $160. The analyst, who continues to view the company as a "premier franchise," sees the stock trading in a range of $120-$180 until the headwinds its facing normalize.
09/13/18
09/13/18
DOWNGRADE

Mixed
Red Hat downgraded to Mixed following checks at OTR Global
As previously reported, OTR Global downgraded Red Hat to Mixed from Positive. The firm's reseller checks indicate most met Q2 license business expectations, but some were impacted by summer slowdowns and pricing changes.
MTEM Molecular Templates
$6.25

2.15 (52.44%)

01/05/18
LTCO
01/05/18
NO CHANGE
Target $17.5
LTCO
Buy
Molecular Templates price target raised to $17.50 from $10 at Ladenburg
CRSP Crispr Therapeutics
$51.90

-1.27 (-2.39%)

05/31/18
JMPS
05/31/18
NO CHANGE
Target $211
JMPS
Outperform
JMP continues to recommend Vertex shares after CTX001 clinical hold
JMP Securities analyst Liisa Bayko said she is "not overly concerned at this point" that cell therapy CTX001 being developed by Vertex (VRTX) with Crispr Therapeutics (CRSP) is on clinical hold until the partners answer questions from the FDA, noting that data are still being generated outside of the U.S. while the IND is in a holding pattern. The analyst, who said she had been getting excited for CTX001 as Vertex has been focused on diversifying its pipeline beyond cystic fibrosis, continues to recommend Vertex shares, citing her belief that 2018 will be another strong year for the company. Bayko maintains her Outperform rating and $211 price target on Vertex.
06/11/18
MSCO
06/11/18
NO CHANGE
MSCO
Equal Weight
Editas CRISPR-related cancer risks seem overblown, says Morgan Stanley
After studies published in Nature Medicine by Novartis (NVS) and the Karolinska Institute suggested an increased risk of cancer that could result from editing genomes with CRISPR-Cas9, Morgan Stanley analyst Matthew Harrison said the concerns are theoretical and noted that STAT's article on the subject does not provide any link to an increased risk for CRISPR activation of p53 versus natural activation when DNA breaks. Harrison thinks theoretical concerns will continue to arise regarding gene editing until the first substantial set of clinical data is generated, but he does not see any direct concerns for Editas Medicine (EDIT) and expects the stock to recover in the coming days. He keeps an Equal Weight rating and $39 price target on Editas shares. Morgan Stanley does not cover Intellia Therapeutics (NTLA) or Crispr Therapeutics (CRSP), which have also seen weakness following the Nature Medicine publications.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $67
PIPR
Overweight
Piper reiterates Overweight on Crispr after ViaCyte collaboration
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics with a $67 price target after the company announced a collaboration with ViaCyte. ViaCyte is developing the stem cell therapy for insulin deficiency, but is currently limited by host rejection, Tenthoff tells investors in a research note. He points out that Crispr will develop gene-edited immuno-evasive properties into the cells, a potentially curative therapy. The analyst believes the collaboration leverages Crispr's gene-editing in diabetes.
07/18/18
JEFF
07/18/18
NO CHANGE
Target $40
JEFF
Buy
Study in Nature Biotech has limited readthrough to Intellia, says Jefferies
A new Nature Biotech publication highlights important safety points, but due to the methods/model systems used, the paper has limited readthrough to Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and Crispr Therapeutics (CRSP) programs advancing to the clinic, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes the experiments used in the paper were not representative and may not have direct implications to current gene-editing clinical-directed strategies. The paper is another example of using a non-optimal model system with too many variables, Raycroft contends. He keeps a Buy rating on Intellia with a $40 price target.
KOS Kosmos
$9.35

0.04 (0.43%)

05/17/18
LEHM
05/17/18
UPGRADE
Target $9.4
LEHM
Overweight
Kosmos upgraded to Overweight from Equal Weight at Barclays
Barclays analyst James Hosie upgraded Kosmos Energy to Overweight and raised his price target for the shares to $9.40 from $7.25. The analyst believes exploration differentiates Kosmos from peers in 2018 and thinks "strong" production and cash flow growth can make the stock an "appealing option" for investors seeking oil price leverage.
06/11/18
JEFF
06/11/18
UPGRADE
Target $9.5
JEFF
Buy
Kosmos upgraded to Buy from Hold at Jefferies
Jefferies analyst Mark Wilson upgraded Kosmos Energy to Buy and raised his price target for the shares to $9.50 from $7.10. The analyst also raised his per-barrel Brent price forecast to $77 from $64 in 2018, to $75 from $60 in 2019, and to $70 from $65 in 2020. Wilson says Kosmos' two-well exploration program offshore Suriname is the most material program across his coverage this year.
07/05/18
RBCM
07/05/18
UPGRADE
Target $10
RBCM
Outperform
Kosmos upgraded to Outperform at RBC Capital on oil outlook, Tortue development
As reported earlier, RBC Capital analyst Al Stanton upgraded Kosmos (KOS) to Outperform from Sector Perform and raised his price target to $10 from $7. The analyst cites his more positive outlook for higher oil price as well as more upbeat BP (BP) commentary on Tortue gas development offshore Mauritania/Senegal. Stanton estimates the company's production growth reaching 50% in FY18, with higher realisations and oil prices in 2019 leading to another 20% increase in output.
07/05/18
RBCM
07/05/18
UPGRADE
RBCM
Outperform
Kosmos upgraded to Outperform from Sector Perform at RBC Capital
VKTX Viking Therapeutics
$19.64

0.17 (0.87%)

09/19/18
MAXM
09/19/18
NO CHANGE
Target $28
MAXM
Buy
Viking Therapeutics price target raised to $28 from $14 at Maxim
Maxim analyst Jason McCarthy raised his price target on Viking Therapeutics to $28 and kept his Buy rating after the company's positive top-line 12-week P2 data announcement for VK2809. The analyst says he is also lowering the "risk in his model" around the program to 30% from 50%, while also looking ahead to the phase 2B study in biopsy-proven NASH and the expected meeting with regulators to discuss the findings in the first half of 2019.
09/19/18
HCWC
09/19/18
NO CHANGE
HCWC
H.C. Wainwright points out Viking is years behind Madrigal, Genfit
In interpreting and reacting to Viking Therapeutics' (VKTX) Phase II VK2809 data yesterday, the market has gotten ahead of itself, especially relative to Madrigal Pharmaceuticals (MDGL) and Genfit (GNFTF), H.C. Wainwright analyst Ed Arce tells investors in a research note. The analyst sees "several significant limitations" of the Viking study, including a small sample size that he says limits the reliability of results, the non-alcoholic fatty liver disease patient population, which he notes is not the same as nonalcoholic steatohepatitis, its LDL reductions being similar to other agents, and the analyst's belief that safety questions remain. Further, he reminds investors that Viking is still, "at best," three-to-four years behind Genfit and Madrigal. The VK2809 efficacy data look strong, but evaluating it by other compounds is comparing apples to oranges, Arce contends. The analyst continues to believe that Genfit's market valuation is "substantially below" its intrinsic value.
09/19/18
RHCO
09/19/18
NO CHANGE
Target $28
RHCO
Buy
Viking Therapeutics price target raised to $28 from $14 at SunTrust
SunTrust analyst Edward Nash raised his price target on Viking Therapeutics to $28 and kept his Buy rating after its "promising" VK2809 phase 2 study results showing "superior % liver fat reduction" with an "encouraging" safety profile. The analyst expects the company to move forward with a Phase II/III study after its discussions with the FDA in early 2019.
09/19/18
ROTH
09/19/18
NO CHANGE
Target $24
ROTH
Buy
Viking Therapeutics price target raised to $24 from $13 at Roth Capital
Roth Capital analyst Scott Henry maintained a Buy rating on Viking Therapeutics and raised his price target to $24 from $13 after the company reported positive phase 2 data for VK2809 for the treatment of non-alcoholic fatty liver disease. In a research note to investors, Henry says key takeaways from the data release include that VK2809 achieved statistical significance versus placebo for both LDL reduction and liver fat reduction, the data was competitive with other compounds, and the next step is likely an FDA meeting in early 2019.

TODAY'S FREE FLY STORIES

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLI

Hollysys

$20.56

0.26 (1.28%)

17:02
02/15/19
02/15
17:02
02/15/19
17:02
Earnings
Hollysys reports Q2 adjusted EPS 73c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

AKS

AK Steel

$2.98

-0.015 (-0.50%)

16:58
02/15/19
02/15
16:58
02/15/19
16:58
Syndicate
Breaking Syndicate news story on AK Steel »

AK Steel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
02/15/19
02/15
16:55
02/15/19
16:55
General news
Treasury Market Summary: i »

Treasury Market Summary:…

LPTX

Leap Therapeutics

$1.65

(0.00%)

16:53
02/15/19
02/15
16:53
02/15/19
16:53
Hot Stocks
Valence Helix Investments discloses 10.99% stake in Leap Therapeutics »

Valence Helix disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$23.25

-0.24 (-1.02%)

16:52
02/15/19
02/15
16:52
02/15/19
16:52
Hot Stocks
Mid Penn Bancorp seeks approval to relocate Allentown Boulevard branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$423.79

8.54 (2.06%)

, AMGN

Amgen

$188.31

1.6 (0.86%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
Regeneron says EPO revokes Immunex's European patent No. 2,990,420 »

Regeneron…

REGN

Regeneron

$423.79

8.54 (2.06%)

AMGN

Amgen

$188.31

1.6 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    Apr

  • 13

    May

UPS

UPS

$110.89

-0.91 (-0.81%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
UPS CFO sells 9.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DAL

Delta Air Lines

$51.09

0.58 (1.15%)

16:43
02/15/19
02/15
16:43
02/15/19
16:43
Syndicate
Breaking Syndicate news story on Delta Air Lines »

Delta Air Lines files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.89

-0.91 (-0.81%)

16:42
02/15/19
02/15
16:42
02/15/19
16:42
Hot Stocks
UPS raises quarterly dividend to 96c per share from 91c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.